Cellavision Introduces New Workflow Solution for Low-Volume Hematology Labs at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022

CellaVision (Lund, Sweden) has announced the launch of DIFF-Line by CellaVision, a new workflow solution for low-volume hematology laboratories at the 2022 AACC Clinical Lab Expo. DIFF-Line by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision DC-1, RAL SmearBox, and RAL StainBox.

CellaVision DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision DC-1 was launched in 2019 and received FDA clearance in October 2020.


Image: The CellaVision booth at AACC 2022 (Photo courtesy of CellaVision)

RAL SmearBox produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision is introducing the RAL SmearBox to the market today July 27, 2022.

RAL StainBox stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals.

DIFF-Line by CellaVision is available on the European market from July 2022 and will be rolled out in more markets in 2022. All CellaVision products are sold through their distribution partners.

“DIFF-Line by CellaVision is a comprehensive solution for small labs that want to improve diagnostic certainty,” said Simon Ostergaard, CellaVision CEO. “With the acquisition of RAL Diagnostics, CellaVision can now offer a complete workflow for smearing, staining, and analyzing peripheral blood smears in hematology labs that handle a smaller amount of daily blood samples.”

Related Links:
CellaVision 


Latest AACC 2022 News